NCT04065945

Brief Summary

The primary purpose of the study is to investigate the relationship between different protocols of assisted reproductive technology and the epigenetic safety of the offspring. Different interventions of assisted reproductive technology include controlled ovarian hyperstimulation (COH), in vitro embryo culture, in vitro fertilization(IVF), intracytoplasmic sperm injection(ICSI), frozen-thawed embryo transfer(FET), preimplantation genetic testing(PGT). The investigators are also interested in the relationship between pregnancy outcomes in ART or natural conception and environmental, nutritional and lifestyle factors.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 12, 2019

Completed
10 days until next milestone

First Posted

Study publicly available on registry

August 22, 2019

Completed
24 days until next milestone

Study Start

First participant enrolled

September 15, 2019

Completed
5.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

August 22, 2019

Status Verified

August 1, 2019

Enrollment Period

5.3 years

First QC Date

August 12, 2019

Last Update Submit

August 21, 2019

Conditions

Outcome Measures

Primary Outcomes (8)

  • live birth rate

    Number of women with live births / number of women randomized to the specific group.Live birth is defined as the delivery of any viable infant at 28 weeks or more of gestation after our interventions.

    1 day after delivery

  • birth weight

    Weight of newborns at delivery.

    1 day after delivery

  • implantation rate

    Implantation rate was defined as the percentage of fetal heart beat among total transferred embryos at 12 weeks' gestational age.

    11-12 weeks after embryo transfer

  • clinical pregnancy rate

    Clinical pregnancy was defined as an observation of gestational sac via ultrasonography.

    6 weeks after embryo transfer

  • congenital anomalies rate

    Congenital anomaly included deformity and development abnormality of any organs or systems.

    1 day after delivery

  • weight

    the weight of offspring

    Change from the date of delivery up to 4 years after delivery

  • height

    the height of offspring

    Change from the date of delivery up to 4 years after delivery

  • Incidence of mental diseases and metabolic dysfunction

    4 years after delivery

Secondary Outcomes (6)

  • biochemical pregnancy rate

    2 weeks after embryo transfer

  • pregnancy loss rate

    28 gestational weeks in maximum

  • ectopic pregnancy rate

    12 gestational weeks in maximum

  • preterm birth rate

    28 gestational weeks to 37 gestational weeks

  • Incidence of moderate to severe ovarian hyperstimulation syndrome(OHSS)

    3 months after controlled ovarian hyperstimulation

  • +1 more secondary outcomes

Study Arms (2)

Couples undergoing ART treatment

Couples in reproductive age undergoing ART treatment in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity \& Child Health Hospital, and Changhai Hospital of Shanghai.

Other: Completion questionnaires/providing biological samples

Couples getting pregnant naturally

Couples who get pregnant naturally and want to deliver the babies in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity \& Child Health Hospital, and Changhai Hospital of Shanghai.

Other: Completion questionnaires/providing biological samples

Interventions

Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.

Couples getting pregnant naturallyCouples undergoing ART treatment

Eligibility Criteria

Age20 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Study subjects will be recruited from couples seeking treatment of infertility or getting pregnant naturally and wanting to deliver their babies at the Women's Hospital School of Medicine Zhejiang University. Men must be at least 22 years old and women must be at least 20 years to participate in the study.

You may qualify if:

  • Couples undergoing treatment for infertility or getting pregnant naturally and wanting to deliver their babies in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity \& Child Health Hospital, and Changhai Hospital of Shanghai.
  • Men 22-55 years old
  • Women 20 - 45 years old

You may not qualify if:

  • Any individual or couple who is outside of age range .
  • Any couple who don't plan to complete their pregnancy check-up or deliver their babies in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity \& Child Health Hospital, or Changhai Hospital of Shanghai.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Women's Hospital School of Medicine Zhejiang University

Hangzhou, Zhejiang, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood, urine, granulosa cells, follicular fluid , sperm and semen ,abandoned egg or embryo,villi, decidua, placenta, amniotic fluid, umbilical cord blood, and buccal swabs of the offspring.

MeSH Terms

Conditions

Infertility

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Study Officials

  • Dan Zhang, M.D, Ph.D

    Women's Hospital School Of Medicine Zhejiang University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Dan Zhang, M.D, Ph.D

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 12, 2019

First Posted

August 22, 2019

Study Start

September 15, 2019

Primary Completion

December 31, 2024

Study Completion

December 31, 2024

Last Updated

August 22, 2019

Record last verified: 2019-08

Locations